ANDA 86026, held by Watson Labs. Hydrochlorothiazide; Spironolactone.
As of Nov 16, 2026, ANDA 86026 (Spironolactone W/ Hydrochlorothiazide), held by Watson Labs, was not approved, with 12 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Spironolactone W/ Hydrochlorothiazide25MG;25MG · tablet;oral | Hydrochlorothiazide; Spironolactone | Discontinued |
| Jan 8, 1987 | Supplement 15Manufacturing | Approved | None posted |
| Jan 8, 1987 | Supplement 16Manufacturing | Approved | None posted |
| Jan 8, 1987 | Supplement 17Manufacturing | Approved | None posted |
| Dec 15, 1986 | Supplement 9Manufacturing | Approved | None posted |
| Dec 15, 1986 | Supplement 12Manufacturing | Approved | None posted |
| Dec 15, 1986 | Supplement 13Manufacturing | Approved | None posted |
| Jul 3, 1986 | Supplement 14Manufacturing | Approved | None posted |
| Apr 22, 1986 | Supplement 11Manufacturing | Approved | None posted |
| Aug 3, 1984 | Supplement 8Manufacturing | Approved | None posted |
| Oct 14, 1983 | Supplement 5Manufacturing | Approved | None posted |
| Apr 8, 1983 | Supplement 2Manufacturing | Approved | None posted |
| Apr 8, 1983 | Supplement 4Manufacturing | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters